IRIS
DE LAURENTIIS, MICHELINO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.125
EU - Europa 1.818
AS - Asia 1.418
AF - Africa 45
SA - Sud America 7
Continente sconosciuto - Info sul continente non disponibili 2
Totale 6.415
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.054
SG - Singapore 840
IT - Italia 707
CN - Cina 424
NL - Olanda 253
IE - Irlanda 180
DE - Germania 159
FI - Finlandia 154
UA - Ucraina 154
VN - Vietnam 99
CA - Canada 68
GB - Regno Unito 64
FR - Francia 48
SE - Svezia 48
CI - Costa d'Avorio 36
IN - India 34
CZ - Repubblica Ceca 8
RU - Federazione Russa 8
BR - Brasile 5
TW - Taiwan 5
BE - Belgio 4
BG - Bulgaria 4
ES - Italia 4
HK - Hong Kong 4
IR - Iran 4
JO - Giordania 4
AL - Albania 3
BZ - Belize 3
CH - Svizzera 3
EG - Egitto 3
PL - Polonia 3
RO - Romania 3
ZA - Sudafrica 3
EU - Europa 2
JP - Giappone 2
KE - Kenya 2
LI - Liechtenstein 2
MD - Moldavia 2
SI - Slovenia 2
CL - Cile 1
DK - Danimarca 1
EC - Ecuador 1
ID - Indonesia 1
KR - Corea 1
LT - Lituania 1
LU - Lussemburgo 1
NO - Norvegia 1
RS - Serbia 1
TN - Tunisia 1
Totale 6.415
Salva come PNG Salva come JPEG
Città #
Singapore 706
Chandler 457
Millbury 270
Amsterdam 239
Santa Clara 199
Jacksonville 160
Princeton 156
Ashburn 122
Naples 121
Nanjing 115
Beijing 98
Dong Ket 98
Napoli 92
Wilmington 88
Des Moines 77
Boston 64
Ottawa 63
Lawrence 48
Milan 41
Nanchang 41
Dublin 28
Hebei 26
Rome 23
Tianjin 23
Norwalk 21
Shenyang 21
Jiaxing 20
Munich 19
Pune 18
Boardman 16
Falls Church 15
Helsinki 14
Houston 14
Kunming 11
Seattle 10
Kronberg 9
Salerno 9
Shenzhen 9
Changsha 8
Fairfield 8
Giugliano In Campania 8
Washington 8
Woodbridge 8
Cookstown 7
Formia 7
New York 7
Pomigliano d'Arco 7
Bologna 6
Casoria 6
Indiana 6
Massa di Somma 6
Redwood City 6
Brno 5
Dearborn 5
Fort Worth 5
Frankfurt am Main 5
Lanzhou 5
London 5
Nuremberg 5
Sant'Agnello 5
Wuhan 5
Amman 4
Catanzaro 4
Changchun 4
Dallas 4
Harrow 4
Kortrijk 4
Leawood 4
Samara 4
Shanghai 4
Sofia 4
Somma Vesuviana 4
Springfield 4
Acton 3
Angri 3
Battipaglia 3
Belize City 3
Craiova 3
Edinburgh 3
Granada 3
Johannesburg 3
Lappeenranta 3
Los Angeles 3
Montauro 3
Olomouc 3
Pavia 3
Pellezzano 3
Perugia 3
Porto 3
San Mateo 3
Sunnyvale 3
Tirana 3
Toronto 3
Ann Arbor 2
Augusta 2
Bernalda 2
Buffalo 2
Cairo 2
Caivano 2
Cambridge 2
Totale 3.826
Salva come PNG Salva come JPEG
Nome #
Manuale di Oncologia Clinica 101
Metabolic and anthropometric changes in early breast cancer patients receiving adjuvant therapy 90
20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years 85
Targeting HER2 as a therapeutic strategy for breast cancer: a paradigmatic shift of drug development in oncology. 82
A randomised factorial trial of sequential doxorubicin and CMF vs CMF and chemotherapy alone vs chemotherapy followed by goserelin plus tamoxifen as adjuvant treatment of node-positive breast cancer. 66
CDK 4/6 Inhibitors as Single Agent in Advanced Solid Tumors. 65
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial 65
Impact of COVID-19 outbreak on cancer immunotherapy in Italy: A survey of young oncologists 62
A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer. 60
Mitoxantrone, etoposide and bleomycin (MEB) chemotherapy in non-Hodgkin's lymphoma patients non-elegible for standard cyclophoshamide, doxorubicin, vincristine and prednisone (CHOP) combination. 55
Adipose microenvironment promotes triple negative breast cancer cell invasiveness and dissemination by producing CCL5 55
Crosstalk between bone niche and immune system: Osteoimmunology signaling as a potential target for cancer treatment. 54
Human epidermal growth factor receptor 2 dual blockade with trastuzumab and pertuzumab in real life: Italian clinical practice versus the CLEOPATRA trial results 52
The evolving therapeutic landscape of trastuzumab-drug conjugates: Future perspectives beyond HER2-positive breast cancer 51
Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype 51
Luminal-like HER2-negative stage IA breast cancer: a multicenter retrospective study on long-term outcome with propensity score analysis 49
Unexpected ovarian activity in premenopausal breast cancer survivors treated with exemestane and GnRH analogues 48
Docetaxel, vinorelbine, and zoledronic acid as first-line treatment in patients with hormone refractory prostate cancer: a phase II study. 47
Imaging tests in staging and surveillance of non-metastatic breast cancer: changes in routine clinical practice and cost implications 46
Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: An open-label, 2 × 2 factorial, randomised phase 3 trial 45
A Metanalysis on the Interaction between HER2 Expression and Response to Endocrine Treatment in Advanced Breast Cancer 44
Demographic, tumor and clinical features of clinical trials versus clinical practice patients with HER2-positive early breast cancer: results of a prospective study 44
Central nervous system metastases in a cohort of metastatic breast cancer patients treated with trastuzumab. 42
Body weight and risk of molecular breast cancer subtypes among postmenopausal Mediterranean women 42
Twenty-year results of the Naples GUN randomized trial: predictive factors of adjuvant tamoxifen efficacy in early breast cancer. 41
Vinorelbine + mitomycin C as second-line treatment of metastatic breast cancer: a two-stage phase 2 study. 41
Artificial neural network analysis of circulating tumor cells in metastatic breast cancer patients. 41
A Feasibilty Study of a Sequential Dose-Dense Adjuvant Regimen with Epidoxorubicin Followed by Docetaxel Followed by High-Dose Cyclophosphamide for Early Breast Cancer with 4 or More Lymph Node Metastases. 41
alpha-Interferon potentiates the growth inhibitory effects of anti-transferrin receptor monoclonal antibodies 41
An interaction network approach to study the correlation between endocrine disrupting chemicals and breast cancer 41
Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI) 41
A-Interferon potentiates the growth inhibitory effects of anti-transferrin receptor monoclonal antibodies. 40
A metanalysis of interaction between HER2 and the response to endocrine therapy (ET) in metastatic breast cancer (MBC)”, 40
Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis 40
A predictive index of axillary nodal involvement in operable breast cancer. 39
Phase I-II study of xelox and bevacizumab plus erlotinib in sequential combination (XELOX-TARAV) in first line colorectal cancer: run in part 39
Prognostic Value of Cancer Stem Cells Markers in Triple-Negative Breast Cancer 39
Programmed Death Ligand 1 (PD-L1) Tumor Expression Is Associated with a Better Prognosis and Diabetic Disease in Triple Negative Breast Cancer Patients 39
Combined effect of obesity and diabetes on early breast cancer outcome: A prospective observational study 39
Adjuvant zoledronic acid and letrozole plus ovarian function suppression in premenopausal breast cancer: HOBOE phase 3 randomised trial 39
Contrast-enhanced harmonic compound US of the spleen to increase staging accuracy in patients with Hodgkin lymphoma: a prospective study. 38
Combination of inositol and alpha lipoic acid in metabolic syndrome-affected women: a randomized placebo-controlled trial 38
C-erbB2 overexpression decreases the benefit of adiuvant tamoxifen in early breast cancer without axillary lymph node metastases. 37
The impact of schedule on acute toxicity and dose-intensity of high-dose chemotherapy with epirubicin and cyclophosphamide plus colony stimulating factors in advanced breast cancer. 37
Amyloid in bone marrow smears of patients affected by multiple myeloma. 37
Metabolic syndrome-breast cancer link varies by intrinsic molecular subtype 37
Triple-Negative Breast Cancer comparison with Canine Mammary Tumors from light microscopy to molecular pathology 37
Low glycemic index diet, exercise and vitamin D to reduce breast cancer recurrence (DEDiCa): design of a clinical trial 36
Virtual reality and music therapy as distraction interventions to alleviate anxiety and improve mood states in breast cancer patients during chemotherapy 36
Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study. 35
Twenty-year results of the Naples GUN randomized trial: predictive factors of adjuvant tamoxifen efficacy in early breast cancer. 35
Prognostic significance of multifocality in primary breast cancer. 35
Antitumor activity of combined blockade of epidermal growth factor receptor and protein kinase A. 35
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. 35
Glucose impairs tamoxifen responsiveness modulating connective tissue growth factor in breast cancer cells 35
Randomised phase 3 open-label trial of first-line treatment with gemcitabine in association with docetaxel or paclitaxel in women with metastatic breast cancer: a comparison of different schedules and treatments. 34
Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: lack of prediction in HER2-positive disease treated with targeted therapy. 34
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer 34
High progesterone levels during the luteal phase related to the use of an aromatase inhibitor in breast cancer patients 34
NUCLEAR DNA CONTENT-DERIVED PARAMETERS CORRELATED WITH HETEROGENEOUS EXPRESSION PF P53 AND BCL-2 PROTEINS IN CLEAR CELL RENAL CARCINOMA 33
Measurement of neovascularization is an independent prognosticator of survival in node-negative breast cancer patients with long-term follow-up. 33
Is there a standard chemotherapeutic regimen for hormone-refractory prostate cancer? Present and future approaches in the management of the disease. 33
Endocrine factors in the outcome of systemic adjuvant therapy of early breast cancer. 33
Second-line chemotherapy with a hybrid-alternating regimen of bolus 5FU modulated by methotrexate and infusional 5FU modulated by folinic acid in patients with metastatic colorectal cancer pretreated with 5FU. A phase 2 study. 33
CMF vs alternating CMF/EV in the adjuvant treatment of operable breast cancer. A single centre randomised clinical trial (Naples GUN-3 study). 33
Treatment of triple negative brest cancer (TNBC): current options and future perspectives. 33
Molecular mechanism and clinical implications of endocrine therapy resistance in breast cancer. 33
HER2 as predictive marker of resistance to endocrine treatment for advanced bresat cancer: a metanalysis of published studies 33
Molecular profiles of screen detected vs. symptomatic breast cancer and their impact on survival: results from a clinical series 33
CD10/common acute lymphoblastic leukemia-associated antigen and adhesion factor expression is predictive for lymphokine-activated killing sensitivity of adult B-lineage acute lymphoblastic leukemia 33
Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials 33
Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial 33
Cardiotoxicity and pro-inflammatory effects of the immune checkpoint inhibitor Pembrolizumab associated to Trastuzumab 33
Metabolic syndrome and early stage breast cancer outcome: results from a prospective observational study 33
Nuclear DNA content-derived parameters correlated with heterogeneous expression of p53 and bcl-2 proteins in clear cell renal carcinomas. 32
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. 32
Bone effect of adjuvant tamoxifen, letrozole or letrozole plus zoledronic acid in early-stage breast cancer: the randomized phase 3 HOBOE study. 32
DNA-flow cytometry (ploidy and s-phase fraction) as prognostic factor in a retrospective series of 515 primary breast-cancer 32
Ado-trastuzumab emtansine (T-DM1) in HER2+ advanced breast cancer patients: does pretreatment with pertuzumab matter? 32
A technique for using neural network analysis to perform survival analysis of censored data. 31
Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): An open-label, randomised phase 3 trial 31
Inhibition of cardiomyocytes late INa with ranolazine to prevent anthracyclines cardiotoxicity in experimental models in vitro and in vivo 31
Taxane-Based Combinations As Adjuvant Chemotherapy of Early Breast Cancer: A Meta-Analysis of Randomized Trials 30
EXPRESSION OF EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) CORRELATES WITH DISEASE RELAPSE AND PROGRESSION TO ANDROGEN-INDEPEDENCE IN HUMAN PROSTATE CANCER. 29
Angiogenesis as a prognostic indicator of survival in non-small-cell lung carcinoma: a prospective study. 29
Prognostic significance of necrosis, elestosis, fibrosis and inflammatory cell reaction in operable breast cancer. 29
Mitomycin C and mitoxantrone in anthracycline-pretreated advanced breast cancer patients. A phase II study. 29
Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials. 29
Endocrine therapy in post-menopausal women with metastatic breast cancer: From literature and guidelines to clinical practice 29
Efficacy and safety of T-DM1 in the 'common-practice' of HER2+ advanced breast cancer setting: A multicenter study 29
Expression of biomarkers modulating prostate cancer progression: Implications in the treatment of the disease 29
c-erbB2 expression predicts tamoxifen efficacy in breast cancer patients. 28
Survival Analysis by means of a novel Neural Network Model 28
Survival, quality of life and breast cancer. 28
Chemotherapy with mitomycin C and vinblastine in pretreated metastatic breast cancer. 28
Chemotherapy-induced nausea and vomiting in Italian cancer centers: results of CINVDAY, a prospective, multicenter study 28
Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials 28
Measurement of neovascularization is an independent prognosticator of survival in node-negative breast cancer patients with long-lerm follow-up. 27
SECOND-LINE CHEMOTHERAPY WITH A HYBRID-ALTERNATING REGIMEN OF BOLUS FLUOROURACIL MODULATED BY METHOTREXATE AND INFUSIONAL FLUOROURACIL MODULATED BY FOLINIC ACID IN PATIENTS WITH METASTATIC COLORECTAL CANCERPRETREATED WITH FLUOROURACIL. A PHASE II STUDY. 27
Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment. 27
Totale 3.980
Salva come PNG Salva come JPEG
Categoria #
all - tutte 36.710
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 36.710
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020344 0 0 0 0 40 15 9 16 13 81 79 91
2020/2021626 20 27 72 46 45 78 49 11 103 17 50 108
2021/20221.113 9 4 10 4 21 50 15 45 175 90 202 488
2022/20231.345 225 95 38 79 130 125 12 81 190 248 100 22
2023/20241.160 44 168 161 77 50 79 13 81 12 22 199 254
2024/20251.287 458 583 42 75 129 0 0 0 0 0 0 0
Totale 6.833